Guidelines of care for the management of acne vulgaris
Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older.
OBJECTIVE: The objective of this study was to provide evidence-based recommendations for the management of acne.
METHODS: A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations.
RESULTS: This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements.
LIMITATIONS: Analysis is based on the best available evidence at the time of the systematic review.
CONCLUSIONS: These guidelines provide evidence-based recommendations for the management of acne vulgaris.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 90(2024), 5 vom: 15. Apr., Seite 1006.e1-1006.e30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reynolds, Rachel V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2023.12.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367894726 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367894726 | ||
| 003 | DE-627 | ||
| 005 | 20240415233144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2023.12.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM367894726 | ||
| 035 | |a (NLM)38300170 | ||
| 035 | |a (PII)S0190-9622(23)03389-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reynolds, Rachel V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines of care for the management of acne vulgaris |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older | ||
| 520 | |a OBJECTIVE: The objective of this study was to provide evidence-based recommendations for the management of acne | ||
| 520 | |a METHODS: A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations | ||
| 520 | |a RESULTS: This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements | ||
| 520 | |a LIMITATIONS: Analysis is based on the best available evidence at the time of the systematic review | ||
| 520 | |a CONCLUSIONS: These guidelines provide evidence-based recommendations for the management of acne vulgaris | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acne | |
| 650 | 4 | |a Cutibacterium acnes | |
| 650 | 4 | |a acne vulgaris | |
| 650 | 4 | |a adapalene | |
| 650 | 4 | |a antiandrogens | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a azelaic acid | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a benzoyl peroxide | |
| 650 | 4 | |a clascoterone | |
| 650 | 4 | |a clindamycin | |
| 650 | 4 | |a contraceptives | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a diet and acne | |
| 650 | 4 | |a doxycycline | |
| 650 | 4 | |a erythromycin | |
| 650 | 4 | |a grading and classification of acne | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a hormonal therapy | |
| 650 | 4 | |a isotretinoin | |
| 650 | 4 | |a light therapies | |
| 650 | 4 | |a microbiological and endocrine testing | |
| 650 | 4 | |a minocycline | |
| 650 | 4 | |a retinoids | |
| 650 | 4 | |a salicylic acid | |
| 650 | 4 | |a sarecycline | |
| 650 | 4 | |a spironolactone | |
| 650 | 4 | |a tazarotene | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a tretinoin | |
| 650 | 4 | |a trifarotene | |
| 650 | 7 | |a Benzoyl Peroxide |2 NLM | |
| 650 | 7 | |a W9WZN9A0GM |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 650 | 7 | |a Retinoids |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 700 | 1 | |a Yeung, Howa |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Carol E |e verfasserin |4 aut | |
| 700 | 1 | |a Cook-Bolden, Fran |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Seemal R |e verfasserin |4 aut | |
| 700 | 1 | |a Druby, Kelly M |e verfasserin |4 aut | |
| 700 | 1 | |a Freeman, Esther E |e verfasserin |4 aut | |
| 700 | 1 | |a Keri, Jonette E |e verfasserin |4 aut | |
| 700 | 1 | |a Stein Gold, Linda F |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Jerry K L |e verfasserin |4 aut | |
| 700 | 1 | |a Tollefson, Megha M |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Jonathan S |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Peggy A |e verfasserin |4 aut | |
| 700 | 1 | |a Zaenglein, Andrea L |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jung Min |e verfasserin |4 aut | |
| 700 | 1 | |a Barbieri, John S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 90(2024), 5 vom: 15. Apr., Seite 1006.e1-1006.e30 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2024 |g number:5 |g day:15 |g month:04 |g pages:1006.e1-1006.e30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2023.12.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2024 |e 5 |b 15 |c 04 |h 1006.e1-1006.e30 | ||